查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099012

肝炎治療市場－全球市場預測（2026-2032年）

Hepatitis Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝炎治療市場將成長至 274.5 億美元，複合年成長率為 6.48%。

主要市場統計數據
基準年 2025 176.7億美元
預計年份：2026年 187.9億美元
預測年份 2032 274.5億美元
複合年成長率 (%) 6.48%

肝炎治療市場執行摘要

隨著根除病毒性肝炎、改善篩檢、透過疫苗接種預防病毒性肝炎以及擴大抗病毒療法的可及性成為公共衛生系統的優先事項，肝炎治療領域正在迅速發展。此領域涵蓋乙型、丙型和丁型肝炎的治療，以及對肝炎、肝硬化、肝細胞癌風險和相關併發症的支持性治療。世界衛生組織（世衛組織）已將病毒性肝炎列為全球重大健康挑戰，其中乙型和丙型肝炎佔肝炎相關發病率和死亡率的絕大多數。這使得人們對有效的抗病毒療法、長期疾病監測、藥物依從性支持和綜合肝臟護理路徑的需求持續成長。

肝炎治療領域的變革性變化

在科學創新、以根除為導向的政策框架以及醫療服務模式改進的推動下，肝炎治療領域正經歷著一場變革。對於C型肝炎而言，泛基因型直接抗病毒藥物（DAA）療法徹底改變了治療前景，在早期診斷並接受持續治療的情況下，可實現短期、耐受性良好且治癒率高。這使得丙型肝炎的管理模式從抑制慢性疾病轉變為基於可規模化治癒的公共衛生策略。

人工智慧對肝炎治療的累積影響

人工智慧 (AI) 透過改善疾病檢測、臨床決策支援、臨床試驗設計、藥物安全監測和患者參與度，對肝炎治療整體產生了累積影響。在診斷和風險分層方面，AI 驅動的分析可以幫助解讀肝臟影像、評估纖維化程度、分析實驗室數值模式和電子健康記錄中的徵兆，並識別需要進行丙型肝炎確診檢測或轉診至專科醫生的患者。這些功能尤其重要，因為許多慢性B型或C型肝炎患者在發展為晚期肝病之前都未被確診。

肝炎治療的關鍵區域見解

亞太地區面臨沉重的肝炎負擔，尤其是慢性B型肝炎，在全球肝炎治療、疫苗接種預防和長期抗病毒治療管理方面發揮核心作用。在人口眾多且公共衛生計畫完善的國家，重點在於新生兒疫苗接種、預防母嬰傳播、擴大篩檢、協調核苷（酸）類似物療法。該地區在根除C型肝炎方面也至關重要，透過泛基因型直接抗病毒藥物、簡化的診療模式和國家採購機制，提高了治療的可近性。然而，農村地區的醫療資源匱乏、經濟負擔、社會歧視以及未確診的感染仍然是重要的障礙。

關於肝炎治療的關鍵群體特異性發現

北約成員國與高所得的歐洲和北美醫療保健系統存在顯著的重疊，這些地區的醫療保健系統可以透過安全相關的醫療保健項目、軍事醫療系統、移民醫療保健項目以及跨境公共衛生協調，為流動性強的群體提供持續的肝炎篩檢、疫苗接種和抗病毒治療。儘管七國集團（G7）國家通常擁有完善的肝炎治療體系、先進的診斷技術、肝移植基礎設施和基於指南的肝病診療，但在診斷和治療方面，社會邊緣群體（例如吸毒者、移民、囚犯和偏遠農村地區的居民）仍然存在不平等現象。

主要國家肝炎治療藥物的使用趨勢

中國是世界上慢性乙型肝炎患者人數最多的國家之一，因此，抗病毒治療的可近性、疫苗接種的歷史影響、肝細胞癌監測以及功能性緩解等方面的研究至關重要。美國在肝炎治療方面擁有強大的臨床能力，並有完善的丙型肝炎治療和慢性乙型肝炎監測指南，但其國家醫療體系仍面臨諸多挑戰，例如診斷不足、複雜的保險制度、藥物濫用相關感染以及醫療服務獲取方面的不平等。日本擁有完善的肝炎篩檢和肝癌監測系統，長期以來致力於在老齡化社會中根除丙型肝炎並管理慢性B型肝炎。印度面臨嚴重的乙型和丙型肝炎負擔，因此，可負擔的診斷、社區治療、血液安全、疫苗接種的實施以及與國家衛生計劃的整合是其首要任務。

為肝炎治療領域的領導者提供的實用建議

行業領導者應優先考慮能夠涵蓋肝炎全過程的治療策略，從診斷到長期肝臟預後。最可行的方案在於支持簡化的、循證的治療路徑，減少啟動治療所需的就診次數，整合反射性檢測，並在法規允許的情況下實現分散式處方。對於C型肝炎，領導者應加強與公共衛生計畫、懲教醫療系統、成癮治療機構、減害服務機構和社區診所的合作，以擴大持續面臨感染風險族群的支持。

丙型肝炎治療分析的調查方法

本執行摘要採用系統性的二手資料研究途徑，利用檢驗的公共衛生、臨床、監管和科學資訊來源編寫而成。此調查方法強調對世界衛生組織指南、國家肝炎控制計劃、同行評審的臨床文獻、監管動態、治療指南、流行病學監測報告以及臨床診療流程中的證據進行橫斷面比對。優先考慮來自權威公共衛生機構、臨床學會、監管機構和已發表醫學研究的數據支持性見解。

結論

肝炎治療正邁入一個更加一體化的時代，其特徵是丙型肝炎的根治性治療、乙型肝炎的持續抑制、丁型肝炎的新治療方案以及功能性治癒研究的加速推進。最顯著的進展體現在篩檢、診斷、抗病毒藥物取得、病患導航、預防計畫和長期肝功能監測等環節，這些環節已被整合到一個連貫的公共衛生路徑中。然而，由於診斷上的不足、醫療資源取得的不平等、醫療保健體系的碎片化、社會歧視以及診斷基礎設施的匱乏，許多患者仍然無法從現有的治療中獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肝炎治療市場：依治療分類

  • 聯合治療
  • 直接作用抗病毒藥物
    • Ns3/4A蛋白酶抑制劑
    • NS5A抑制劑
    • NS5B聚合酵素抑制劑
    • 泛基因型治療方案
  • 干擾素
  • 核苷酸類似物

第8章 肝炎治療市場：依基因型分類

  • 基因型 1
    • 基因型 1A
    • 基因型 1B
  • 基因型 2
  • 基因型 3
  • 基因型 4
  • 基因型 5
  • 基因型 6

第9章 肝炎治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第10章 肝炎治療市場：依通路分類

  • 線上
  • 離線

第11章 肝炎治療市場：依疾病階段分類

  • 急性
  • 慢性的

第12章 肝炎治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 肝炎治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 肝炎治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Arbutus Biopharma Corporation
  • Assembly Biosciences Inc
  • Bayer AG
  • Biocon Limited
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Dynavax Technologies Corporation
  • Enanta Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Hetero Healthcare Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co. Inc
  • Mirum Pharmaceuticals
  • NATCO Pharma Limited
  • Novartis International AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
Product Code: MRR-450A0628DE07

The Hepatitis Therapeutics Market is projected to grow by USD 27.45 billion at a CAGR of 6.48% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.67 billion
Estimated Year [2026] USD 18.79 billion
Forecast Year [2032] USD 27.45 billion
CAGR (%) 6.48%

Hepatitis Therapeutics Executive Summary

Hepatitis therapeutics are advancing rapidly as public health systems prioritize viral hepatitis elimination, improved screening, vaccination-linked prevention, and broader access to antiviral treatment. The category spans therapies for hepatitis B, hepatitis C, hepatitis D, and supportive management of liver inflammation, cirrhosis, hepatocellular carcinoma risk, and related complications. The World Health Organization identifies viral hepatitis as a major global health challenge, with hepatitis B and hepatitis C responsible for most hepatitis-related morbidity and mortality. This creates sustained demand for effective antiviral regimens, long-term disease monitoring, adherence support, and integrated liver care pathways.

The current hepatitis therapeutics landscape is shaped by high-efficacy direct-acting antivirals for hepatitis C, nucleos(t)ide analogs for chronic hepatitis B, emerging options for hepatitis D, and growing interest in finite-duration functional cure strategies. Clinical priorities increasingly focus on earlier diagnosis, simplified treatment initiation, resistance monitoring, prevention of liver disease progression, and equitable access in high-burden populations. As healthcare providers shift from specialty-only treatment models toward decentralized care, hepatitis therapeutics are becoming closely linked with diagnostics, digital health, harm-reduction programs, maternal health services, HIV services, and primary care infrastructure.

Transformative Shifts in the Hepatitis Therapeutics Landscape

The hepatitis therapeutics landscape is undergoing transformative shifts driven by scientific innovation, elimination-focused policy frameworks, and improved care delivery models. For hepatitis C, pangenotypic direct-acting antiviral regimens have changed treatment expectations by enabling short-course, well-tolerated therapy with high cure rates when patients are diagnosed and retained in care. This has repositioned hepatitis C management from chronic disease suppression toward scalable cure-based public health strategies.

For hepatitis B, long-term viral suppression remains central, but research momentum is increasingly directed toward functional cure approaches that combine antiviral suppression with immune modulation and targeted mechanisms against viral persistence. The persistence of covalently closed circular DNA and integrated viral DNA continues to be a major biological barrier, making combination strategies an important area of therapeutic development. Hepatitis D has also gained greater clinical visibility because coinfection with hepatitis B is associated with faster liver disease progression, and therapeutic progress has elevated the need for routine hepatitis D screening among people with hepatitis B.

Healthcare system transformation is equally important. Simplified diagnostic algorithms, point-of-care testing, reflex viral load confirmation, dried blood spot testing where appropriate, and task-shifting to trained non-specialists are improving treatment initiation in underserved settings. At the same time, payer policies, national hepatitis action plans, prison health programs, opioid-use disorder services, harm-reduction networks, and antenatal screening initiatives are reshaping access to hepatitis therapeutics across populations that historically experienced delayed diagnosis or fragmented care.

Cumulative Impact of Artificial Intelligence on Hepatitis Therapeutics

Artificial intelligence is creating cumulative impact across hepatitis therapeutics by improving disease detection, clinical decision support, trial design, pharmacovigilance, and patient engagement. In diagnostics and risk stratification, AI-enabled analytics can support interpretation of liver imaging, fibrosis assessment, laboratory patterns, and electronic health record signals to identify patients who may require confirmatory hepatitis testing or specialist referral. These capabilities are especially relevant because many people living with chronic hepatitis B or hepatitis C remain undiagnosed until advanced liver disease develops.

In therapeutic research, machine learning is being applied to target identification, molecule screening, immune-response modeling, and patient stratification for functional cure programs. AI-assisted analysis can help evaluate viral kinetics, host immune markers, treatment response predictors, and safety signals across complex datasets. For clinical operations, predictive tools may improve site selection, trial recruitment, protocol feasibility, and retention among populations with comorbidities such as HIV infection, substance use disorders, metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and chronic kidney disease.

AI also supports real-world hepatitis care by identifying adherence risks, automating follow-up reminders, and enabling population health teams to track testing-to-treatment cascades. However, implementation requires validated algorithms, transparent governance, representative datasets, privacy protection, bias monitoring, and clinician oversight. The cumulative value of AI in hepatitis therapeutics will depend on its integration into evidence-based care pathways rather than standalone technology deployment.

Key Regional Insights in Hepatitis Therapeutics

Asia-Pacific carries a substantial hepatitis burden, particularly for chronic hepatitis B, making the region central to global hepatitis therapeutics access, vaccination-linked prevention, and long-term antiviral management. Countries with large populations and established public health programs are emphasizing birth-dose vaccination, mother-to-child transmission prevention, expanded screening, and linkage to nucleos(t)ide analog therapy. The region is also important for hepatitis C elimination efforts, where pangenotypic direct-acting antivirals, simplified care models, and national procurement mechanisms are improving treatment availability, although rural access, affordability, stigma, and undiagnosed infection remain persistent barriers.

Europe benefits from mature clinical guidelines, broad access to antiviral treatment, structured surveillance, and strong pharmacovigilance systems, though regional differences remain between Western, Central, and Eastern Europe in screening uptake, harm-reduction coverage, migrant health services, and treatment continuity. North America demonstrates strong adoption of hepatitis C curative therapy, advanced liver disease monitoring, and guideline-driven treatment across specialty and primary care settings. The region benefits from robust laboratory infrastructure and established reimbursement pathways, but gaps persist among people who inject drugs, incarcerated populations, uninsured individuals, Indigenous communities, and people experiencing homelessness. Hepatitis B management is supported by vaccination programs, antenatal screening, and chronic disease monitoring, while public health agencies continue to emphasize catch-up testing and treatment linkage.

Latin America is strengthening hepatitis therapeutics through national viral hepatitis plans, public-sector procurement, and gradual expansion of diagnostic access. Hepatitis B prevalence varies significantly by geography, with higher burden reported in parts of the Amazon basin and Indigenous populations, while hepatitis C treatment programs increasingly rely on simplified regimens and decentralized delivery. Africa has a high chronic hepatitis B burden and substantial unmet need for diagnosis and treatment, with therapeutic progress closely tied to vaccination coverage, antenatal testing, affordable viral load diagnostics, and integration of hepatitis care into HIV and primary health services. The Middle East faces heterogeneous hepatitis epidemiology, with hepatitis C historically prominent in specific countries and hepatitis B remaining a key concern in others; therapeutic access is improving through national elimination programs, blood safety controls, specialty liver services, and expanded screening.

Key Group Insights in Hepatitis Therapeutics

NATO countries overlap significantly with high-income European and North American health systems, where security-related healthcare planning, military medicine, migrant health systems, and cross-border public health coordination can support hepatitis screening, vaccination, and continuity of antiviral treatment for mobile populations. G7 countries generally show high availability of approved hepatitis therapeutics, advanced diagnostics, liver transplant infrastructure, and guideline-based hepatology care, yet continue to face inequities in diagnosis and treatment among marginalized populations, including people who inject drugs, migrants, incarcerated people, and underserved rural communities.

BRICS economies represent a critical share of global hepatitis therapeutic need because of their population scale, diverse epidemiology, and expanding domestic healthcare capacity. These countries are investing in vaccination, antiviral access, local clinical expertise, public-sector treatment pathways, and liver disease surveillance, while confronting challenges related to underdiagnosis, uneven specialist distribution, diagnostic affordability, and regional disparities. The European Union has advanced hepatitis care through harmonized clinical guidance, pharmacovigilance systems, public health commitments to viral hepatitis elimination, and cross-country evidence exchange, although differences in national reimbursement, prison screening, migrant health services, and harm-reduction availability affect progress across member states.

ASEAN countries are increasingly aligning hepatitis therapeutics with universal health coverage, maternal health programs, and infectious disease control infrastructure. Chronic hepatitis B remains a major priority due to perinatal and early-life transmission patterns, while hepatitis C programs are advancing through simplified testing and broader access to direct-acting antivirals. Variation in diagnostic capacity, reimbursement, and rural healthcare access continues to influence treatment uptake across the bloc. The GCC is characterized by strong health system investment, high screening capacity in several member states, and growing emphasis on migrant health, blood safety, chronic liver disease management, and specialty care pathways. Hepatitis therapeutics in the region are shaped by national prevention programs, liver clinics, and efforts to improve early detection among diverse resident populations.

Key Country Insights in Hepatitis Therapeutics

China carries one of the world's largest chronic hepatitis B populations, making antiviral treatment access, vaccination legacy effects, hepatocellular carcinoma surveillance, and functional cure research highly relevant. The United States has strong clinical capacity for hepatitis therapeutics, with broad guideline support for hepatitis C treatment and chronic hepatitis B monitoring, yet the national care cascade remains challenged by underdiagnosis, insurance complexity, substance-use-associated transmission, and gaps in linkage to care. Japan has advanced hepatitis screening and liver cancer surveillance capabilities, with a long-standing focus on hepatitis C cure and chronic hepatitis B management in an aging population. India faces substantial hepatitis B and hepatitis C burdens, with priorities including affordable diagnostics, decentralized treatment, blood safety, vaccination implementation, and integration with national health programs.

Germany, the United Kingdom, France, Italy, and Spain maintain strong specialist networks, reimbursement systems, and guideline-based access to hepatitis C cures and hepatitis B suppression, although migrant health, aging liver disease populations, risk-based screening gaps, and continuity of harm-reduction services remain important policy issues. The United Kingdom also supports hepatitis C elimination through national health service programs, prison testing, and community-based models, while hepatitis B care focuses on migrant populations, antenatal screening, and long-term monitoring. Russia faces a complex hepatitis burden requiring expanded diagnostics, treatment linkage, chronic liver disease management, and stronger surveillance integration.

Australia has made measurable progress in hepatitis C treatment access and harm-reduction-linked care, while hepatitis B management is closely tied to culturally appropriate services for migrant and Indigenous communities. South Korea combines strong clinical infrastructure with active hepatitis B management, liver cancer surveillance, and expanding attention to earlier diagnosis and treatment optimization. Canada emphasizes public health screening, Indigenous health equity, harm reduction, and access to curative hepatitis C therapy, while chronic hepatitis B care is closely linked to immigrant health and long-term liver cancer surveillance. Brazil has developed public-sector experience in antiviral delivery and viral hepatitis surveillance, with regional differences in hepatitis B endemicity and ongoing efforts to improve access across remote and underserved areas. Mexico is expanding hepatitis C elimination initiatives and diagnostic access, with continued need for broader screening and simplified treatment pathways.

Actionable Recommendations for Hepatitis Therapeutics Leaders

Industry leaders should prioritize therapeutic strategies that address the full hepatitis care cascade, from diagnosis to long-term liver outcomes. The most actionable opportunity lies in supporting simplified, evidence-based treatment pathways that reduce the number of visits required before therapy initiation, integrate reflex testing, and enable decentralized prescribing where permitted by regulation. For hepatitis C, leaders should strengthen partnerships with public health programs, correctional health systems, addiction medicine providers, harm-reduction services, and community clinics to reach populations with ongoing transmission risk.

For hepatitis B, investment should focus on functional cure research, treatment adherence, biomarker development, liver cancer surveillance integration, and patient education for long-term disease management. For hepatitis D, routine screening among hepatitis B patients should be supported through clinician education and diagnostic access initiatives. Across all hepatitis types, healthcare stakeholders should improve real-world evidence generation, pharmacovigilance, health equity measurement, and patient-reported outcome tracking.

Digital and AI-enabled tools should be deployed with clinical validation and equity safeguards, particularly for identifying undiagnosed patients and preventing loss to follow-up. Leaders should also align access strategies with national elimination targets, strengthen affordability mechanisms in high-burden countries, support workforce training, and expand community-based delivery models to move hepatitis therapeutics beyond specialist centers into scalable public health pathways.

Research Methodology for Hepatitis Therapeutics Analysis

This executive summary is developed through a structured secondary research approach using verified public health, clinical, regulatory, and scientific sources. The methodology emphasizes triangulation across international health agency guidance, national hepatitis action plans, peer-reviewed clinical literature, regulatory updates, treatment guidelines, epidemiological surveillance reports, and real-world care cascade evidence. Priority is given to data-backed insights from recognized public health institutions, clinical societies, regulatory bodies, and published medical research.

The analysis avoids market sizing, revenue estimation, market share evaluation, and forecasting. Instead, it focuses on therapeutic evolution, disease burden context, access dynamics, regional healthcare infrastructure, policy drivers, clinical practice trends, and innovation pathways. Regional, group, and country insights are assessed through comparative review of hepatitis B, hepatitis C, and hepatitis D priorities, including vaccination impact, screening coverage, treatment availability, harm-reduction integration, maternal health strategies, affordability, and liver disease monitoring.

Quality control includes consistency checks across sources, exclusion of unverified claims, and alignment with current evidence-based terminology in hepatology and infectious disease care. The result is an optimized, industry-focused synthesis designed to support strategic understanding of hepatitis therapeutics without relying on speculative commercial projections.

Conclusion

Hepatitis therapeutics are entering a more integrated era defined by curative hepatitis C treatment, sustained hepatitis B suppression, emerging hepatitis D options, and accelerating research toward functional cure. The strongest progress is occurring where screening, diagnostics, antiviral access, patient navigation, prevention programs, and long-term liver monitoring are combined into cohesive public health pathways. However, underdiagnosis, inequitable access, fragmented care, stigma, and limited diagnostic infrastructure continue to prevent many patients from benefiting from available therapies.

Future leadership in hepatitis therapeutics will depend on evidence-based innovation, equitable delivery, and stronger alignment with viral hepatitis elimination goals. Stakeholders that invest in simplified care models, high-burden population outreach, validated digital tools, affordable diagnostics, and durable therapeutic advances will be best positioned to improve clinical outcomes and reduce hepatitis-related liver disease. The strategic imperative is clear: effective hepatitis therapeutics must be paired with accessible testing, timely treatment initiation, prevention of transmission, and lifelong liver health management where needed.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatitis Therapeutics Market, by Therapeutic Class

  • 7.1. Introduction
  • 7.2. Combination Therapies
  • 7.3. Direct Acting Antivirals
    • 7.3.1. Ns3/4A Protease Inhibitors
    • 7.3.2. Ns5A Inhibitors
    • 7.3.3. Ns5B Polymerase Inhibitors
    • 7.3.4. Pan Genotypic Regimens
  • 7.4. Interferons
  • 7.5. Nucleotide Analogues

8. Hepatitis Therapeutics Market, by Genotype

  • 8.1. Introduction
  • 8.2. Genotype 1
    • 8.2.1. Genotype 1A
    • 8.2.2. Genotype 1B
  • 8.3. Genotype 2
  • 8.4. Genotype 3
  • 8.5. Genotype 4
  • 8.6. Genotype 5
  • 8.7. Genotype 6

9. Hepatitis Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral

10. Hepatitis Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Online
  • 10.3. Offline

11. Hepatitis Therapeutics Market, by Stage Of Disease

  • 11.1. Introduction
  • 11.2. Acute
  • 11.3. Chronic

12. Hepatitis Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Hepatitis Therapeutics Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Hepatitis Therapeutics Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Arbutus Biopharma Corporation
  • 16.3. Assembly Biosciences Inc
  • 16.4. Bayer AG
  • 16.5. Biocon Limited
  • 16.6. Bristol Myers Squibb Company
  • 16.7. Cipla Limited
  • 16.8. Dr. Reddy's Laboratories Ltd
  • 16.9. Dynavax Technologies Corporation
  • 16.10. Enanta Pharmaceuticals Inc
  • 16.11. F. Hoffmann-La Roche Ltd
  • 16.12. Gilead Sciences Inc
  • 16.13. GlaxoSmithKline plc
  • 16.14. Hetero Healthcare Limited
  • 16.15. Johnson & Johnson
  • 16.16. Laurus Labs Limited
  • 16.17. Lupin Limited
  • 16.18. Merck & Co. Inc
  • 16.19. Mirum Pharmaceuticals
  • 16.20. NATCO Pharma Limited
  • 16.21. Novartis International AG
  • 16.22. Sun Pharmaceutical Industries Limited
  • 16.23. Teva Pharmaceutical Industries Ltd
  • 16.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATITIS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NS5A INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NS5A INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NS5A INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAN GENOTYPIC REGIMENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PAN GENOTYPIC REGIMENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAN GENOTYPIC REGIMENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEOTIDE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEOTIDE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEOTIDE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOTYPE 1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOTYPE 1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOTYPE 1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOTYPE 1A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOTYPE 1A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOTYPE 1A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOTYPE 1B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOTYPE 1B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOTYPE 1B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOTYPE 2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOTYPE 2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOTYPE 2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOTYPE 3 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOTYPE 3 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOTYPE 3 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOTYPE 4 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOTYPE 4 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOTYPE 4 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOTYPE 5 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOTYPE 5 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOTYPE 5 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOTYPE 6 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOTYPE 6 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOTYPE 6 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 141. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 148. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 150. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. G7 HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DIRECT ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY GENOTYPE 1, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 327. GLOBAL HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025